Proton therapy eliminates 70% of liver cancer tumors – A Korean study

Share This Post

Researchers at Samsung Medical Center in South Korea published a study showing that proton therapy is an effective and safe method of treating liver cancer. Proton therapy is a high-end radiotherapy method that uses proton rays instead of the photon rays (X-ray and γ-ray) used in ordinary radiotherapy to destroy cancer cell DNA, interfere with its replication and reproduction, and cause cancer cell death.

The team of Park Hee-chul and Yu Jeong-il, professors of the Department of Radiation Oncology at Samsung Medical Center, studied 101 liver cancer patients who had undergone proton therapy for one year from January 2016. The results of the study showed that almost all patients who used proton therapy as a substitute for local cautery therapy (such as surgery or high-frequency hyperthermia) were significantly improved.

78 patients were followed up for 3 months after proton therapy. About 70% (54 patients) tumors completely disappeared and about 18% (14 patients) tumors shrank significantly. After treatment, in the Child-Pugh score, nearly 90% of patients maintained Grade A status in the Child-Pugh score for 3 months.

The researchers said that patient safety is considered to be the biggest advantage of proton therapy and has been confirmed by research. Samsung Medical Center pointed out that proton therapy can reduce the adverse effects of existing radiation therapy, and only a lower dose of radiation can achieve better treatment results. “Although we are in the initial stage of developing proton therapy, data published in developed countries: In the long run, proton therapy will bring positive results to patients,” Professor Park said.

Professor Park Hee-chul South Korea

Prof Park Hee-Chul

“Through further research, we will focus on improving the quality of life of patients, through further research to improve the treatment effect and improve the treatment side effects,” Park added. The results were published in the latest issue of the Korean Society of Radiation Oncology (KOSRO).

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form